Gut Microbial Metabolites and Biochemical Pathways Involved in Irritable Bowel Syndrome: Effects of Diet and Nutrition on the Microbiome

Shanalee C James,1,2,3,4 Karl Fraser,1,2,4 Wayne Young,1,2,4 Warren C McNabb,2,4 and Nicole C Roy1,2,4

Abstract

The food we consume and its interactions with the host and their gut microbiota affect normal gut function and health. Functional gut disorders (FGDs), including irritable bowel syndrome (IBS), can result from negative effects of these interactions, leading to a reduced quality of life. Certain foods exacerbate or reduce the severity and prevalence of FGD symptoms. IBS can be used as a model of perturbation from normal gut function with which to study the impact of foods and diets on the severity and symptoms of FGDs and understand how critical processes and biochemical mechanisms contribute to this impact. Analyzing the complex interactions between food, host, and microbial metabolites gives insights into the pathways and processes occurring in the gut which contribute to FGDs. The following review is a critical discussion of the literature regarding metabolic pathways and dietary interventions relevant to FGDs. Many metabolites, for example bile acids, SCFAs, vitamins, amino acids, and neurotransmitters, can be altered by dietary intake, and could be valuable for identifying perturbations in metabolic pathways that distinguish a “normal, healthy” gut from a “dysfunctional, unhealthy” gut. Dietary interventions for reducing symptoms of FGDs are becoming more prevalent, but studies investigating the underlying mechanisms linked to host, microbiome, and metabolite interactions are less common. Therefore, we aim to evaluate the recent literature to assist with further progression of research in this field. J Nutr 2020;150:1012–1021.

Keywords: irritable bowel syndrome, functional gut disorder, gut microbiota, metabolites, diet

Introduction

The human gut is integral to well-being, with interactions between the diet, gut, and the resident microbiota affecting normal gut function and health. Functional gut disorders (FGDs), including irritable bowel syndrome (IBS), can result from negative effects of these interactions, leading to a reduced quality of life. Certain foods exacerbate or reduce the severity and prevalence of FGD symptoms. IBS can be used as a model of perturbation from normal gut function with which to study the impact of foods and diets on the severity and symptoms of FGDs and understand how critical processes and biochemical mechanisms contribute to this impact. Analyzing the complex interactions between food, host, and microbial metabolites gives insights into the pathways and processes occurring in the gut which contribute to FGDs. The following review is a critical discussion of the literature regarding metabolic pathways and dietary interventions relevant to FGDs. Many metabolites, for example bile acids, SCFAs, vitamins, amino acids, and neurotransmitters, can be altered by dietary intake, and could be valuable for identifying perturbations in metabolic pathways that distinguish a “normal, healthy” gut from a “dysfunctional, unhealthy” gut. Dietary interventions for reducing symptoms of FGDs are becoming more prevalent, but studies investigating the underlying mechanisms linked to host, microbiome, and metabolite interactions are less common. Therefore, we aim to evaluate the recent literature to assist with further progression of research in this field.

Critical Review

The Journal of Nutrition
molecules that influence biological functions throughout the body. Alterations to metabolite production in the gut from either host, microbiota, or their interactions may link to FGD symptoms (5).

SCFAs, vitamins, bile acids (BAs), lipids, neurotransmitters, and amino acids are metabolites that can be produced or modified by the host or the gut microbiota (6). Excess or insufficient production of these metabolites, compared with normal homeostatic amounts, could signal disruptions to pathways important to gut and overall health (3). Metabolites produced can be used or further modified by the host or microorganisms, highlighting the complexity of the gut environment and the requirement for comprehensive measurement of these metabolites.

The European Food Safety Authority has recognized IBS as a relevant model of gut comfort and function that shows variation from the norm and applies to the general population (7). Because diet and nutrition are popular as interventions for alleviating FGDs, and because people with IBS are motivated to find solutions (including by modifying their food consumption), investigating the responses to dietary changes in this context is a useful approach for understanding mechanisms behind FGDs.

**Metabolites Linked to IBS**

**BAs**

BA profiles are affected by diet, host characteristics, age and life stages, and the resident microbiota, with recent research showing BA metabolism may be linked to IBS (8–13). There is evidence for variation in the concentration of primary and secondary BAs in plasma in IBS participants (12).

Primary BAs are produced in the liver from cholesterol via the enzyme cholesterol 7-α-hydroxylase, to produce 7-α-hydroxy-4-cholesten-3-one (C4), which is then converted into the 2 primary BAs: chenodeoxycholic acid (CDCA) and cholic acid (CA) (Figure 1). These BAs are conjugated to either taurine or glycine, stored in the gallbladder, secreted into the gut lumen after digestion, and then unconjugated from taurine and glycine by bacterial bile salt hydrolase (BSH) enzymes (13, 14). Most BAs (95%) are reabsorbed and recycled via the hepatic circulation, which is controlled by fibroblast growth factor 15 (FGF15) and the BA receptor farnesoid X receptor (15). Five percent of BAs escape this process and undergo modification by microorganisms with the 7α-dehydroxylase enzyme, resulting in secondary BAs with altered structures that may interact differently with cellular receptors, potentially having impacts on the functionality of metabolites (13). It is unknown if BA concentrations fluctuate owing to differences or disruptions in the ileal epithelial transporter, FGF15 molecules, precursor mechanisms in the liver, or microbial modification of the metabolites.

A meta-analysis of studies reporting on IBS-D symptoms showed that BA malabsorption (BAM) was evident in 16.9–35.3% of the individuals diagnosed with IBS-D (16). BAM is linked to diarrhea, where defective BA recycling or over-production may increase colonic BA concentrations, leading to the onset of laxation (15, 17, 18). Conversely, a reduction in BA concentrations in the colonic mucosa may have the opposite effect, causing constipation and slowing colonic transit. In a study by Sadik et al. (18), BAM was positively associated with accelerated colonic transit in patients with chronic diarrhea (18). However, not all BAs have the same effect on the gut. Unlike CDCA and CA, which are predominantly recycled, the secondary BA lithocholic acid is poorly reabsorbed, instead passing through to the colon for further modification by bacteria and then excretion (19). The action of CDCA may be facilitated by activation of intracellular secretory channels, increased mucosal permeability, or decreased fluid and electrolyte absorption (20).

Differences in fecal and serum BA concentrations are observed in individuals with IBS-C and IBS-D and may correlate with visceral pain and colonic transit (17, 21, 22). In the feces of IBS-D individuals, primary BAs were higher and secondary BAs lower in concentration than in healthy controls, suggesting BAM and the inability of BAs to be modified by the gut microbiota (23). Positive correlations were evident between concentrations of C4 and FGF19, stool weight, and total BAs in IBS-D individuals, suggesting an increase of BA production to counteract BAs lost in fecal samples. Interestingly, the relative abundance of the fecal microbiota in IBS-D individuals was characterized by reduced concentrations of *Bifidobacterium* (<1 log10 difference) and *Clostridium leptum* (>1 log10 difference), bacteria possessing BSH enzymes involved in BA transformation (23).

David et al. (24) investigated how dietary intake over 5 d influenced the gut microbiota and metabolites. In this study, they showed that an animal-based diet, compared with a plant-based diet, increased the abundance of BAs in fecal samples, which they surmised was due to higher amounts of cholesterol (a precursor of BAs) in animal-based diets. Consequently, based on the relation between dietary patterns, BA metabolism, microbial enzymatic activities, host epithelium, hepatic portal circulation, and metabolism, BA fluctuations could provide valuable insight into understanding the mechanisms contributing to the onset and severity of IBS.

**SCFAs**

Carbohydrates that escape digestion in the stomach are passed intact to the small and large intestines where the gut microbiota

---

**FIGURE 1** BA production and processes within the body. BAs are produced in the liver from cholesterol, followed by their storage in the gallbladder. After food intake, BAs are excreted out into the gut lumen, where they act as detergent molecules to aid in the absorption of nutrients. In the large intestine, they are converted to secondary BAs owing to the action of microbes possessing the bile salt hydrolase enzyme. Created with BioRender. BA, bile acid; CA, cholic acid; CDCA, chenodeoxycholic acid; GCA, glyco-cholic acid; GDCA, glyco-chenodeoxycholic acid; TCA, tauro-cholic acid; TDCA, tauro-chenodeoxycholic acid.
ferments them into SCFAs (3, 25, 26). Acetate, propionate, and butyrate are the primary SCFAs produced in the gut (27). Approximately 80–90% of SCFAs produced in the colon are used by the body, with the rest excreted in feces (26).

Many bacteria can produce SCFAs, including butyrate. Some of the most common butyrate producers include *Fecalibacterium prausnitzii*, *Roseburia* spp., *Eubacterium rectale*, and *Eubacterium hallii* (28–30). Butyrate is produced via pathways utilizing lactate, acetate, sugars, and amino acids that may be by-products produced by other bacteria (29). Of the 3 pathways producing propionate, the succinate pathway is the most common and performed predominantly by *Bacteroides* spp. and *Veillonella* spp. (29). Acetate production pathways are more widespread, produced from a range of fermented carbohydrates and by a range of microbes (29, 31). Colonocytes predominantly use butyrate for energy, whereas propionate is utilized by the liver in gluconeogenesis and acetate circulates throughout the body (31, 32). Acetate and propionate are linked to the regulation of glucose homeostasis, fatty acid concentrations in the liver, and stimulating energy and appetite regulation, suggesting that relative proportions of specific SCFAs could be more important than total abundance (31).

Alterations in microbial composition and butyrate and propionate concentrations are evident in individuals with IBS compared with healthy controls (33, 34). Lower butyrate concentrations in IBS could indicate a disrupted energy supply to large intestinal colonocytes with consequences for IBS symptoms (34). A different study reported no difference in fecal acetate, propionate, butyrate, and lactate between controls and IBS participants, although total SCFA abundance was lower in the IBS-C subtype than in other subtypes (IBS-D, IBS-M) (35). Tana et al. (33) showed higher SCFA concentrations in fecal samples of IBS participants along with an increased relative abundance of *Veillonella* and *Lactobacillus*, a consistent observation because *Lactobacillus* prominently produces lactic and acetic acids, whereas *Veillonella* transforms lactic acid to acetic acid and propionic acid (33). There was a positive correlation between fecal SCFA concentration and symptom severity, signifying a possible association between metabolite production and gut discomfort (33).

The relation between SCFAs and IBS is inconsistent in the literature, because there is evidence for both higher and lower SCFA concentrations in IBS (5, 36, 37). A potential explanation for this variation is the functional redundancy of a microbial community where if one species is reduced in abundance, another species may fill the vacated niche, potentially contributing the same metabolites (e.g., SCFAs) to the system. Consequently, understanding the interaction between dietary patterns, SCFA concentration, host functions, and gut microbial activity, including species abundance, could be relevant to successfully elucidating a possible link to IBS (5, 33).

**Vitamins**

Perturbations in vitamin concentrations have been linked to IBS (38). Vitamins are obtained directly from dietary intake or are biosynthesized in the body. However, sufficient quantities required for the effective functioning of cellular processes may not be met by dietary intake and the host alone (39, 40). Some species of the human gut microbiota, for example lactic acid bacteria, can synthesize folate, thiamin, biotin, vitamin K, nicotinic acid, pantothenic acid, pyridoxine, and riboflavin, which may be utilized by the host (3, 39–42). These vitamins can have essential roles within the body, for example folate, which is vital in DNA replication (39). David et al. (24) noted subjects consuming animal-based dietary patterns had increased microbes with vitamin-synthesizing genes compared with those on plant-based dietary patterns, highlighting the potential role of diet, microbiota, and metabolome relations.

Vitamin B-6 (pyridoxine) has been linked to inflammatory conditions and, therefore, could be important in IBS (38, 43). In a study investigating the dietary intake of 17 individuals with IBS, a low vitamin B-6 concentration correlated to a high IBS symptom score (38). Consistent with other B-vitamins, vitamin B-6-producing pathways can be found in species from Actinobacteria, Bacteroidetes, and Proteobacteria phyla, with fewer synthesizing capabilities found in Firmicutes (40).

Magnúsdóttir et al. (44) investigated the B-vitamin-producing capacity of 256 gut microbial genomes, finding 40–65% encoded for biosynthetic pathways necessary to synthesize 8 key vitamins (biotin, cobalamin, folate, niacin, pantothenate, pyridoxine, riboflavin, and thiamin) (44). Riboflavin, an activator of mucosal-associated invariant T cells and essential in cellular metabolism as a precursor to FAD and FMN, had synthesizing genes present in 166 of the 256 annotations (39, 45). Niacin synthesis was the second most prevalent pathway, present in 162 gene annotations (44). The biosynthesis of riboflavin was found predominantly in Bacteroidetes, Proteobacteria, and Fusobacteria, with low amounts in Firmicutes and no gene pathways in Actinobacteria, in contrast to niacin pathways which were uniformly distributed over the 5 phyla (44). Differences in vitamin-synthesizing capability across different taxa raise the potential for vitamin production to vary between healthy individuals and those with IBS (44). Interestingly, Firmicutes, often found in high abundance in IBS compared with healthy individuals, was the only phylum analyzed without all 8 vitamin synthesis pathways (27, 44, 46, 47). However, mathematical modeling indicated the gut microbiota could only produce 4 of the 8 vitamins in concentrations that could have clinical relevance (44). These estimates are based solely on computational modeling and, therefore, investigating the rate and source of both host and microbial vitamin production is required because the presence of vitamin-synthesizing genes does not necessarily correlate to clinical outcomes. In addition, investigating the absorption of host- and microbially produced vitamins using methods such as stable isotope probing is needed. A more in-depth understanding of host and microbial interactions could help to elucidate further roles for vitamins in IBS, and the clinical significance of microbially produced vitamins.

**Amino acids**

Tryptophan is an essential amino acid obtained from dietary patterns and is an important precursor for serotonin. Therefore, it has been hypothesized that tryptophan may be an important amino acid in IBS, owing to the relative importance of serotonin (5-HT) in FGDs (48). However, an examination of plasma tryptophan concentration in IBS individuals showed no difference to healthy controls (48). Two competitive pathways, the kynurenine and serotonin pathways, metabolize tryptophan into either the vitamin niacinamide or the neurotransmitters 5-HT/melatonin (48, 49). Although tryptophan concentrations may not differ, the balance between the kynurenine pathway and the serotonin pathway may be important because of the different biological functions of the resulting metabolites (48–51).
Investigation of urinary metabolites between individuals with IBS, ulcerative colitis (UC), and healthy controls found histidine, lysine, glutamine, proline, and glutamic acid concentrations varied between IBS and UC participants, but not from healthy controls (52). Ornithine, a metabolite of the urea cycle, was the only amino acid that varied between IBS and healthy controls, with a lower concentration in IBS participants (52). However, a dietary analysis was not completed in this study. Glutamine is involved in energy supply to the epithelial cells of the gut and consequently a depletion could be crucial in IBS symptomology. When given as an oral supplement (5 g 3 times/d), glutamine reduced IBS symptom severity in individuals with postinfectious IBS-D (53). In general, understanding the possible role of amino acid metabolism in IBS requires further research to investigate their clinical relevance.

**Neurotransmitters**

The neurotransmitter 5-HT is produced in the gut and affects neuronal signals in the brain, highlighting its importance in gut–brain responses (54). Ninety-five percent of 5-HT is produced by the enterochromaffin cells of the gut epithelium, whereas the other 5% is produced in serotonergic neurons (54–56). 5-HT in the gut is assumed to activate neurons linked to pain, sensitivity, and reflexes via enterochromaffin and enteroendocrine cells (57, 58). The biological activity of 5-HT is terminated by serotonin reuptake transporter (SERT), the recycling mechanism for 5-HT in the body (54, 58). An overproduction of 5-HT can lead to overactivation of nerve sensing mechanisms, causing increased hypersensitivity (55). It is possible that polymorphisms in SERT may influence IBS, although studies investigating the possible association between 5-HT, the SERT gene, and IBS subtypes have had varying results (56). Atkinson et al. (59) found a lack of 5-HT uptake was associated with IBS-D symptoms owing to the deletion of a base fragment (59), whereas others concluded there was no relation between the SERT polymorphism and IBS (60, 61).

In the gut of individuals with IBS, enterochromaffin cell counts and concentrations of 5-HT were higher than in healthy controls (54). However, such differences in enterochromaffin cells are not consistently observed in the literature (62, 63). Mast cell concentration was increased in the mucosal layer of the IBS group, suggesting activation of the immune system as a causal factor in the pain and discomfort associated with IBS. Supporting this finding, the authors noted the severity of visceral pain and hypersensitivity felt by IBS participants correlated to 5-HT release (54).

Dopamine and γ-aminobutyric acid (GABA) are key neurotransmitters which may be implicated in IBS. Dopamine, a neurotransmitter of the catecholamine family, is linked to depression and anxiety (64) and has been found at lower concentrations in individuals with IBS than in healthy controls (52). In addition, GABA, which exerts important anti-inflammatory effects, was reduced in IBS-D individuals compared with healthy controls (65).

**Inflammatory molecules**

Cytokines are metabolites linked to inflammatory responses (66). TNF-α, a proinflammatory molecule, and the anti-inflammatory cytokines IL-10 and transforming growth factor β1 (TGF-β1), have potential importance in IBS (66, 67). Polymorphisms in the genetic components encoding these cytokines may increase or decrease in concentration, causing disruptions to inflammatory responses (66). Gonsalkorale et al. (66) found an association between IBS symptoms and reduced IL-10 concentrations compared with healthy controls. Another investigation showed that the concentrations of IL-β1, IL-6, and TNF-α were higher in IBS-D participants than in healthy controls (65). A meta-analysis of 9 studies showed gender differences in TNF-α and IL-10 blood concentrations in patients with IBS (56, 68). However, results from another meta-analysis showed no correlation between TGF-β1 and IBS (69). In general, the importance and relevance of inflammatory molecules in IBS remain unclear but plausible.

**Putative biomarkers of FGDs**

A biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention” (70). When considering diagnostic biomarker panels, both specificity and sensitivity are important for application in the clinical setting (71). Sensitivity refers to the true positive value where the biomarkers must accurately select for the true positives while ensuring false negatives are not selected (72). Conversely, specificity refers to the accurate selection of the true negative value, and no selection of false positives (72). Ideally, biomarkers need to be easy to measure and cost-effective in a clinical setting (8).

Studies have reported panels of metabolites in different biological matrices between IBS and non-IBS participants with varying degrees of specificity and sensitivity (Table 1). In most cases, a high sensitivity and specificity is achieved by measuring a range of metabolic markers, and therefore the applicability for an effective and efficient diagnosis, although appropriate for research settings, would be limited in clinical settings. Current biomarker panels fail to address the underlying biochemical mechanisms and pathways that cause IBS, and therefore although diagnosis may be possible, effective treatment options remain elusive. Although biomarker panels are moving toward understanding IBS, there remains scope for significant improvement.

**Impact of Dietary Intake on IBS**

Between 60% and 89% of individuals with an FGD found that dietary patterns exacerbate their symptoms, resulting in individuals excluding or including certain foods or even whole food groups from or into their diet (76–82). Caution must be taken in adopting dietary regimens for IBS because they can disrupt how and why specific metabolites are produced. In a study of 36,448 individuals from France (dietary data, Rome III Diagnostic Criteria), 1,870 people diagnosed with IBS had different food consumption patterns than healthy controls (83). Reduced intake of protein and micronutrients (e.g., vitamins) was characteristic of IBS individuals, attributed to lower intakes of milk, yogurt, and fruit (83). The study’s findings are consistent with previous results where people believed lactose intolerance was a contributing factor to their symptoms (84, 85).

Evidence for how the removal of whole food groups can affect microbial composition and successive metabolites has been shown in studies comparing predominantly animal- or plant-based dietary patterns in healthy cohorts. An animal-based diet increased the relative abundance of *Alisipes*, *Bilophila*, and *Bacteroides* and decreased proportions of microbes known to degrade plant compounds (e.g., *Roseburia*, *E. rectale*, and *Bilophila*).
### TABLE 1 Biomarker panels for discrimination of IBS

| Biomarkers                                      | Sample type | Sample cohort       | Sample size | Sensitivity | Specificity | Reference                  |
|------------------------------------------------|-------------|---------------------|-------------|-------------|-------------|----------------------------|
| 1. IL-1B                                        | Serum       | IBS, IBD, celiac disease, HC | IBS, n = 876; IBD, n = 398; celiac disease, n = 57; HC, n = 235 | 50%         | 88%         | Lembo et al. (73)           |
| 2. Growth related oncogene-α                    |             |                      |             |             |             |                            |
| 3. Brain-derived neurotroph factor              |             |                      |             |             |             |                            |
| 4. Anti-Saccharomyces cerevisiae antibody        |             |                      |             |             |             |                            |
| 5. Antibody against bacterial flagellin (CBir1) |             |                      |             |             |             |                            |
| 6. Antihuman tissue transglutaminase            |             |                      |             |             |             |                            |
| 7. TNF-like weak inducer of apoptosis           |             |                      |             |             |             |                            |
| 8. Antineutrophil cytoplasmic antibody          |             |                      |             |             |             |                            |
| 9. Tissue inhibitor of metalloproteinase-1      |             |                      |             |             |             |                            |
| 10. Neutrophil gelatinase-associated lipocalin  |             |                      |             |             |             |                            |

Ten original biomarkers from Lembo et al. (73) and 24 additional biomarkers:

| Biomarkers                                      | Sample type | Sample cohort       | Sample size | Sensitivity | Specificity | Reference                  |
|------------------------------------------------|-------------|---------------------|-------------|-------------|-------------|----------------------------|
| 1. Histamine                                    | Serum       | IBS, HC             | IBS, n = 188; HC, n = 76 | 81%         | 64%         | (74)                       |
| 2. PGE2                                         |             |                      |             |             |             |                            |
| 3. Tryptase                                     |             |                      |             |             |             |                            |
| 4. Serotonin                                    |             |                      |             |             |             |                            |
| 5. Substance P                                  |             |                      |             |             |             |                            |
| 6. IL-1                                         |             |                      |             |             |             |                            |
| 7. IL-10                                        |             |                      |             |             |             |                            |
| 8. IL-6                                         |             |                      |             |             |             |                            |
| 9. IL-8                                         |             |                      |             |             |             |                            |
| 10. TNF-like weak inducer of apoptosis          |             |                      |             |             |             |                            |
| 11. 14 gene expression markers (CBFA2T2, CCDC147, HSD17B11, LDLR, MAP6D1, MICAL1, RAB7L1, RNF26, RRPP7A, SUSD4, SH3BGRL3, VIPR1, WEE1, ZNF326) |             |                      |             |             |             |                            |
| 12. IL-1B                                       | Fecal and plasma | IBS, HC            | IBS, n = 196; HC, n = 160 | 88.1%       | 86.5%       | (71)                       |
| 13. IL-6                                        |             |                      |             |             |             |                            |
| 14. IL-12p70                                    |             |                      |             |             |             |                            |
| 15. TNF-like weak inducer of apoptosis          |             |                      |             |             |             |                            |
| 16. Chromogranin A                              |             |                      |             |             |             |                            |
| 17. Human β-defensin 2                          |             |                      |             |             |             |                            |
| 18. Calprotectin                                 |             |                      |             |             |             |                            |
| 19. Caproate                                    |             |                      |             |             |             |                            |

Breath IBS, HC IBS, n = 170; HC, n = 153 | 89.4% | 73.3% | (75) |

1HC, healthy control; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome.

*Ruminococcus bromii* (24). This study concluded a predominantly animal-based dietary intake rapidly altered microbial composition within 1 d, but the population returned to its original composition within 2 d after the withdrawal of the diet (24). Alterations to BA and SCFA profiles were observed with both diets (24), emphasizing dietary intake has the potential to affect the host and microbial metabolome. In addition, the microbial transcriptome in those consuming a predominantly animal-based compared with a predominantly plant-based dietary pattern showed increased expression of microbial genes involved in key metabolic pathways, for example, vitamin biosynthesis (24). A similar study comparing the microbiota of children from Italy and Africa found that Italian children who consumed more protein in their dietary intake had higher concentrations of *Alisipes* and *Bacteroides* (86, 87). In contrast, African children consuming more legumes and vegetables had...
higher counts of *Prevotella* and *Succinivibrio* microbes capable of degrading fiber and polysaccharides (87). Fiber intake between the 2 groups of children showed positive correlations to fecal SCFAs, highlighting metabolite production from the lower gut microbiota (87).

### Microbial production of gases

Hydrogen gas, a product of microbial carbohydrate fermentation, is produced by numerous members of the gut microbiota (88, 89). Hydrogen is further used through cross-feeding to produce methane, hydrogen sulfide, and acetate by methanotrophic, sulfate-reducing, and acetogenic bacteria, respectively (90). These molecules are produced solely from the gut microbiota and reabsorbed into the body (88). An excess of hydrogen gas can cause discomfort for healthy and IBS individuals. Firmicutes are the primary hydrogen producers of the gut (88) and are often found in higher quantities in IBS patients with a corresponding decrease in Bacteroidetes, which may explain the common bloating and discomfort symptoms in IBS. This hypothesis is supported by the higher concentrations of breath hydrogen in IBS individuals than in healthy controls (91, 92). King et al. (92) and Dear et al. (93) both noted reduced consumption of foods known to promote hydrogen production decreased symptoms of IBS (92, 93). In addition, an increase in methane concentration is linked to a decrease in gut motility that is evident in IBS-C patients (94).

### Fermentable oligo-di-monosaccharides and polyols

Fermentable oligo-di-monosaccharides and polyols (FODMAPs) are low-fermentable oligosaccharides (e.g., wheat, fructo-oligosaccharides), disaccharides (e.g., lactose), monosaccharides (e.g., honey, fructose), and polyols (e.g., certain fruits, sorbitol) that are assumed to be poorly digested and easily fermented. There is evidence that dietary regimens which exclude or reduce FODMAPs alleviate the pain and distension associated with IBS symptoms (78, 95). The association between reduced IBS symptoms and a low dietary FODMAP intake is well defined but primarily based on symptom improvement as the outcome measure, which can be subjective, rather than biochemical or mechanistic alterations (78, 96–99). Analysis by McIntosh et al. (100), where IBS participants were randomly assigned to either a low- or a high-FODMAP dietary intervention and then given a Kristalose® sachet, predominantly used as a lactulose supplement for constipation, used breath tests to measure volatile metabolites of microbial fermentation (100). Results showed an increase in hydrogen concentration in the high-FODMAP group compared with the low-FODMAP group from baseline over the 21-d period. In this study, methane concentration showed no variation, suggesting a low-FODMAP diet may not differentially alter microbial gas production (100). Both groups had similar baseline urine metabolite profiles, but after dietary intervention, 3 metabolites (histamine, azelaic acid, and p-hydroxybenzoic acid) showed variable differences (100). Urinary histamine, an immune response molecule, was higher in concentration (0.0085 μmol/mmol compared with 0.0008 μmol/mmol) in the high- than in the low-FODMAP intervention (100), in line with other findings that histamine is linked to hypersensitivity and immune activation (101, 102).

Dietary patterns, for example, normal dietary guidelines often given to IBS patients, are different to a low-FODMAP dietary regime because they involve the removal of specific foods, rather than whole food groups. Analysis of a low-FODMAP dietary intake compared with normal dietary guidelines often given to IBS patients for 4 wk showed a similar decrease in symptom severity (96). IBS dietary guidelines were focused mainly around the timing of meals, eating regular meals, avoidance of large meals, and reducing the intake of fat, caffeine, cabbage, beans, and onions (96). Further investigation into potential side-effects of a FODMAP dietary regime is required, because the removal of key food groups could present unfavorable conditions within the gut ecosystem and to the wider body. FODMAPs are often used as prebiotic supplements (103). Consequently, the widespread movement for their removal to reduce the symptoms of FGDs is paradoxical, considering the beneficial effects of prebiotics are mediated by microbial fermentation, yet the adverse effects of FODMAPs are also mediated by microbial fermentation. This is consistent with findings where *Bifidobacteria*, a butyrate-producing bacterium, was reduced after consumption of a 4-wk low-FODMAP diet (concentration 7.4 log_{10} cells/g feces) compared with normal dietary intake (concentration 8.2 log_{10} cells/g feces) (98, 103). Furthermore, SCFAs known to benefit the gut environment through a variety of mechanisms are produced from the fermentation of FODMAPs by the gut microbiota (103, 104). Although there is evidence to suggest a low-FODMAP diet is warranted in IBS, it is crucial that further studies aim to better understand the impact of FODMAP removal in the dietary pattern of healthy individuals compared with those with IBS.

### Probiotics

Probiotics or foods with added beneficial bacteria have been investigated extensively for their ability to alleviate IBS symptoms, with the majority based on outcome measures of abdominal pain, bloating, and IBS symptoms (105–108). Two interventions showed improvement in symptoms after consumption of probiotics, where metabolic or microbial features were also recorded as outcome measures (109, 110). IBS-D participants given 100 g probiotic yogurt each day [7 log_{10} *Lactobacillus fermentum* (American Type Culture Collection (ATCC) 14931) CFU per gram and 7 log_{10} *Lactobacillus plantarum* (ATCC 14917) CFU per gram] for 4 wk showed beneficial changes to symptom scores, abdominal pain, and quality of life together with a reduction in fecal calprotectin from baseline (109). Fecal calprotectin is a marker of inflammation, prevalent at increased concentrations in inflammatory bowel disease. Yoon et al. (110) gave participants either a multistrain probiotic capsule [*Bifidobacterium bifidum* (KCTC12200BP), *Bifidobacterium lactis* (KCTC11904BP), *Bifidobacterium longum* (KCTC12200BP), *Lactobacillus acidophilus* (KCTC11906BP), *Lactobacillus rhamnosus* (KCTC12202BP), and *Streptococcus thermophilus* (KCTC11870BP); total 5 × 10^9 viable cells] or a placebo daily for 4 wk (110). Abdominal pain and bloating were both reduced in the probiotic group compared with the placebo group, although there was no difference in stool form or frequency in either group (110). Measurement of fecal microbiota showed 3 (B. lactis: 6.09 log_{10} cells/g feces to 7.57 log_{10} cells/g feces; L. rhamnosus: 2.80 log_{10} cells/g feces to 5.05 log_{10} cells/g feces; and *S. thermophilus*: 4.81 log_{10} cells/g feces to 5.35 log_{10} cells/g feces) probiotic species were increased after the intervention (110). These findings show modification and disturbances to the gut microbiome may be instrumental in understanding the underlying mechanisms linked to IBS.
Bifidobacteria 1018 James et al.

constipation symptoms (111–115). The soluble components of been investigated for their ability to beneficially alter IBS, which are all characterized by high dietary fiber content, have consumed foods may reduce the symptoms and prevalence of There is an increasing awareness that some commonly con-

spective progresses and on alleviating symptoms, including constipation, associated with IBS. Created with BioRender. IBS, irritable bowel syndrome.

High-fiber foods

There is an increasing awareness that some commonly con-

sumed foods may reduce the symptoms and prevalence of IBS. Prunes, psyllium husk, wholegrain powders, and kiwifruit, which are all characterized by high dietary fiber content, have been investigated for their ability to beneficially alter IBS constipation symptoms (111–115). The soluble components of dietary fiber, for example fructans and inulin, are utilized by the gut microbiota as energy sources, promoting the growth of some beneficial bacteria, for example, Lactobacillus and Bifidobacteria (111, 116, 117). Insoluble fiber, for example, cellulose, is utilized less by the gut microbiota but is essential because it increases gut transit time by passing through the colon undissolved (117). Kiwifruit has a high nutritional value and for many years has been recommended to individuals with IBS-C (Figure 2). The high vitamin C content, actinidin (a unique protease abundant in kiwifruit), and amino acids (glutathione, arginine, and GABA) coupled with a high water-swelling capacity may be responsible for alleviating constipation symptoms (111). The effect of Hayward green kiwifruit (Actinidia delicosa var.) on individuals with IBS-C showed differences in symptom measures after the intervention (115). Consumption of 2 kiwifruit compared with 2 placebo capsules (glucose powder) per day showed decreased colonic transit time and increased weekly defecation in the kiwifruit-consuming participants (115). Prunes have also been shown to be effective in decreasing colonic transit and increasing stool consistency to treat chronic constipation (112). Forty participants with chronic constipation were given either prunes or psyllium (11 g twice daily) as part of a randomized crossover study (112). Both interventions improved complete spontaneous bowel movement compared with baseline, but consumption of prunes decreased colonic transit time compared with psyllium (112). Prunes also resulted in softer stool than did psyllium, with both interventions improving straining when trying to pass fecal matter compared with baseline. The improvement in symptoms from these studies highlights the relevance of using dietary interventions to understand better the mechanisms behind FGDs and their use in alleviating prevalence.

Conclusions

The underlying mechanisms governing the interaction between dietary patterns, the gut microbiota, and the host are still unclear in IBS. New evidence suggests that research and clinical practices should move away from solely relying on symptoms as a diagnostic and results-based tool. Understanding variations and fluctuations in the concentrations of host- or microbial-derived metabolites that can be used to infer processes contributing to the symptoms and severity of IBS will provide important new insights for FGD research.

In this review, we have discussed 2 main themes, the first being critical metabolites linked to IBS, and the second being studies analyzing dietary interventions to reduce the symptoms and severity of IBS. There is increasing literature focused on the clinical aspect (including dietary solutions) of reducing IBS symptoms, but analyses that further investigate the mechanisms behind the success of interventions are less common. The metabolites discussed in this review are a few key metabolic groups potentially important in understanding IBS. A decrease or increase in production of these metabolites could theoretically disrupt metabolic processes throughout the body; however, further investigation is required. Data from the literature suggest that understanding the biochemical pathways and respective metabolic products will help to identify metabolic biomarkers that could be indicative of a “dysfunctional, unhealthy” gut.

There is overwhelming evidence to suggest the microbiome is involved in FGDs; however, whether this is causative or correlative needs further investigation. Less research is focused on investigating the microbiota’s potential in FGDs; however, future research needs to supplement clinical studies that aim to determine the underlying mechanisms. Defining an improvement in, for example, colonic transit time does little in improving our understanding of why some individuals develop FGDs when others do not, and how we can alleviate the prevalence of FGDs worldwide. For advancements to be made, investigations that undertake dietary interventions should be followed by a thorough analysis of the gut microbiota and both host and microbial metabolites. Critically, this will accommodate not just a better understanding of the epidemiology of FGDs but also recommendations for dietary intakes to alleviate symptoms. Dietary guidelines based on studies that lack mechanical evidence may result in the adoption of dietary regimens that lead to beneficial outcomes, but equally may be detrimental after long-term adherence owing to unintentional impacts on other biological mechanisms.

Acknowledgments

The authors’ responsibilities were as follows—SCJ, WY, KF, NCR, and WCM: conceptualized the study; NCR and
WCM: managed the resources and project administration; SCJ: prepared the original draft; WY, KF, NCR, and WCM: reviewed and edited the paper and performed supervision; and all authors: read and approved the final manuscript.

References

1. Lacy BE, Meairn F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. Gastroenterology 2016;150(6):1393–1407.e5.
2. Speder AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, Hungan APS, Kang JY, Minhu C, Schmulson M, et al. Global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut 2017;66(6):1075–82.
3. Vernocchi P, Del Chierico F, Putignani L. Gut microbiota profiling: metabolomics based approach to unravel compounds affecting human health. Front Microbiol 2016;7:1144.
4. De Preter V, Verbeke K. Metabolomics as a diagnostic tool in gastroenterology. World J Gastrointest Pharmacol Ther 2013;4(4):97–107.
5. Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011;141(5):1792–801.
6. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science 2012;336(6086):1262–7.
7. EFSA Panel on Dietetic Products, Nutrition and Allergies. Guidance on the scientific requirements for health claims related to gut and immune function. EFSA J 2011;9(4):2084.
8. Camilleri M, Halawi H, Oduyebo I. Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we? Expert Rev Gastroenterol Hepatol 2017;11(4):303–16.
9. Camilleri M. What’s new in functional and motility disorders in the lower GI tract? Malta Med J 2017;29(2):3–13.
10. Camilleri M, Shin A, Busciglio I, Carlson P, Acosta A, Bharucha AE, Burton D, Lamsam J, Lueke A, Donato LJ, et al. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil 2014;26(12):1677–85.
11. Camilleri M, Oduyebo I, Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. Am J Physiol Gastrointest Liver Physiol 2016;311(5):G777–84.
12. Long SL, Gahan CGM, Joyce SA. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med 2017;56:54–65.
13. Joyce SA, Gahan CGM. Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu Rev Food Sci Technol 2016;7:313–33.
14. Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, Chen T, Qu C, Rajani C, Dong B, et al. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol 2017;15(1):120.
15. Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, Rhoten D, Lueke A, Saenger A, Girtman A. Bile functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013;11(10):1270–5.e1.
16. Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhea. Aliment Pharmacol Ther 2015;42(1):3–11.
17. Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, Bondar O, Dyer RB, Lamsam J, Zinsmeister AR. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012;10(9):1099–15.e3.
18. Sadik R, Abrahamsen H, Ung K-A, Stotzer P-O. Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol 2004;99(4):711–8.
19. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296(5571):1313–6.
20. Odusni-Shivanbate ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, Lamsam J, Singh R, Zinsmeister AR. Effects of chenoeloxylate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010;8(2):159–65.e5.
21. Dior M, Delgrériverie H, Duboc H, Jouet P, Coffin B, Brot L, Humbert L, Trugnan G, Seksik P, Sokol H, et al. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol Motil 2016;28(9):e1330–40.
22. Vijayvargiya P, Busciglio I, Burton D, Donato L, Lueke A, Camilleri M. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin Gastroenterol Hepatol 2018;16(4):522–7.
23. Duboc H, Ranteau D, Rajia S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24(6):e247–e313.
24. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505(7484):559–63.
25. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JJ. Human nutrition, the gut microbiome and the immune system. Nature 2011;474(7351):327–36.
26. Huda-Faujan N, Abdulamir A, Fatimah A, Anas OM, Shuhaimi M, Yazid A, Loong Y. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochim J 2010;4:53.
27. Mayer EA, Savidge T, Shulman RJ. Brain–gut microbiome interactions and functional bowel disorders. Gastroenterology 2014;146(6):1500–12.
28. Vital M, Karch A, Peiper DH. Colonic butyrate-producing communities in humans: an overview using omics data. mSystems 2017;2(2):e00130–17.
29. Barbara G, Feinle-Bisset C, Ghoshal UC, Santos J, Vanner SJ, Vergnolle N, Zoetendal EG, Quigley EM. The intestinal microbiome and functional gastrointestinal disorders. Gastroenterology 2016;150(6):1305–18.e8.
30. Lous P, Young P, Holtrop G, Flint HJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate transferase gene. Environ Microbiol 2012;14(2):304–14.
31. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016;7(3):189–200.
32. Lin HV, Frassetto A, Kowalik EJ, Jr, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012;7(7):e35240.
33. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22(5):e512–e115.
34. Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids—a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol 2016;16(1):51.
35. Ringel-Kulka T, Choi CH, Temas D, Kim A, Maier DM, Scott K, Galanko JA, Ringel Y. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol 2015;110(9):1339–46.
36. Mortensen P, Andersen J, Arffmann S, Krag E. Short-chain fatty acids in inflammatory bowel disease: an overview using omics data. mSystems 2017;2(1):e00130–17.
37. Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with irritable bowel syndrome symptoms. Nutr Res 2011;31(5):356–61.
38. Ligaarden SC, Farup PG. Low intake of vitamin B6 is associated with irritable bowel syndrome symptoms. Nutr Res 2011;31(5):356–61.
LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24(2):160–8.

Yoshi K, Hisomi K, Sawane K, Kunisawa J. Metabolism of dietary and microbial vitamin B family in the regulation of host immunity. Front Nutr. 2019;6:48.

O’Connor E, Barrett E, Fitzgerald G, Hill C, Stanton C, Ross R. Production of vitamins, exopolysaccharides and bacteriocins by probiotic bacteria. In: Tamime A, editor. Probiotic dairy products. Oxford: Blackwell; 2005. pp. 167–94.

10. Hill M. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 1997;6(Suppl 1):543–5.

11. Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Lombardi EM, Mäkivuokko H, Kajander K, Palva A. Microbial community analysis reveals high levels of phylotype associations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009;9(1):95.

12. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reattangoor R. MRI presents microbial vitamin B metabolites to MAIT cells. Nature 2012;491(7426):717–23.

13. Jeffery IB, O’Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, Smirn M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012;61(7):997–1006.

14. Krogius-Kurikka L, Lyra A, Malinen E, Aarninkkajas J, Tiumala J, Paulin L, Mäkiäxookk H, Kajander J, Palva A. Microbial community analysis of the metabolomic profiles of irritable bowel syndrome patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther 2012;36(12):1198–208.

15. Clarke G, Fitzgerald P, Cryan JF, Cassidy EM, Quigley EM, Dinan TG. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol 2009;9(1):6.

16. Clarke G, McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. A distinct profile of tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor activation in irritable bowel syndrome. Front Pharmacol 2012;3:90.

17. Kesheti AH, Madsen KL, Mandel R, Boekxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dielemann LA. Comparison of the metabolic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther 2019;49(6):723–32.

18. Zhou Q, Verne ML, Fields JZ, LeFante JH, Basra S, Salameh H, Verne GN. Randomised placebo-controlled trial of dietary gluten supplements for postponement of irritable bowel syndrome. Gut 2019;68(6):996–1002.

19. Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Gruny D, Tononi M, De Ponti F, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011;106(6):1290–8.

20. Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, Knaggs A, Asquith S, Taylor I, Bahari B. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004;53(10):1452–8.

21. Makker J, Chilimuri S, Bella JN. Genetic epidemiology of irritable bowel syndrome. World J Gastroenterol 2015;21(40):11353–61.

22. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132(1):397–414.

23. Martin CR, Osadchiy V, Kalani A, Mayer EA. The brain-gut-microbiome axis. Cell Mol Gastroenterol Hepatol 2018;6(2):133–48.

24. Atkinson W, Lockhart S, Whorwell PJ, Keelvi B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130(1):34–43.

25. Pata C, Erdal ME, Derici E, Yazar A, Kann K, Ulu O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol 2002;97(7):1780–4.

26. Lee DY, Park H, Kim WH, Lee SI, Seo YJ, Choi YC. Serotonin transporter gene polymorphism in healthy adults and patients with irritable bowel syndrome. Korean J Gastroenterol 2014;64(1):18–22.

27. Faure C, Patey N, Gauthier C, Brooks EM, Maeg MW. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology 2010;139(1):249–58.

28. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Maeg MW, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126(7):1657–64.

29. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64(3):327–37.

30. Aggarwal S, Ahuja V, Paul J. Dysregulation of GABAergic signalling contributes in the pathogenesis of diarrhea-predominant irritable bowel syndrome. J Neurogastroenterol Motil 2018;24(3):422.

31. Gonsalkorale W, Perez C, Pravica V, Whorwell P, Hutchinson I. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52(11):91–3.

32. Komuro H, Sato N, Sasaki A, Suzuki N, Kano M, Tanaka Y, Yamaguchi-Kabata Y, Kanazawa M, Warita H, Aoki M, et al. Corticotropin-releasing hormone receptor 2 gene variants in irritable bowel syndrome. PLoS One 2011;6(11):e20174.

33. Bashashati M, Rezaei N, Shaheyyoun A, McKernan DP, Chang L, Ohman L, Quigley EM, Schumon M, Sharkey KA, Smirn M. Cytochrome imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2014;26(7):1036–48.

34. Bashashati M, Rezaei N, Bashashati H, Shaheyyoun A, Daryani NE, Sharkey KA, Storr M. Cytokeine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2012;24(12):e1102–e16.

35. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89–95.

36. Mujaic Z, Tigchelaar EF, Zhernakov A, Ludwig T, Ramiro-Garcia C, Batanska A, Swertz MA, Masceee AAM, Wijnenga C, Van Schooten FJ, et al. A novel biomarker panel for irritable bowel syndrome and the application in the general population. Sci Rep 2016;6:2420.

37. Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R. Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol 2008;56(1):45–50.

38. Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009;29(8):834–42.

39. Jones M, Chey W, Singh S, Gong H, Shringarpure R, Hoe N, Chuang E, Talley N. A biomarker panel and psychological morbidty differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther 2014;39(4):426–37.

40. Baranska A, Mujaic Z, Smolinska A, Dallinga J, Jonkers D, Tigchelaar E, Dekens J, Zhernakov A, Ludwig T, Masceee A, et al. Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach. Aliment Pharmacol Ther 2016;44(1):43–56.

41. Tack CJ, Vanner SJ. Dietary therapies for functional bowel symptoms: recent advances, challenges, and future directions. Neurogastroenterol Motil 2018;30(1):13288.

42. Hayes P, Corish C, O’Mahony E, Quigley EA. A dietary survey of patients with irritable bowel syndrome. J Hum Nutr Diet 2014;27(2):36–47.

43. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir GJ. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146(1):67–75.e5.
Dietary metabolites in irritable bowel syndrome 1021